Company Of The Day: Merck
What?
Merck (NYSE:MRK) and AstraZenica’s cancer drug Lynparza has been approved by the U.S. FDA to treat patients with early-stage breast cancer with certain mutations.
So What?
Relevant Articles
- Is There A Better Pick Over Merck Stock In Animal Health Space?
- Will Merck Stock Rise After Its Q1 Results?
- What’s Next For Merck Stock After A 6% Fall In A Month?
- Will Merck Stock Rise After Its Q4 Results?
- Here’s A Better Pharmaceutical Pick Over Merck Stock
- What’s Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill?
Merck’s alliance revenue from Lynparza stood at about $989 million in 2021, growing 36% year-over-year, making it one of the company’s fastest-growing drugs. It’s likely that the new approval could increase sales further.
See Our Complete Analysis For Merck
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Mar 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| MRK Return | 2% | 2% | 33% |
| S&P 500 Return | -4% | -12% | 88% |
| Trefis MS Portfolio Return | -4% | -14% | 238% |
[1] Month-to-date and year-to-date as of 3/14/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates